Abstract
Background We previously reported inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity in 1-5% of unvaccinated patients with life-threatening COVID-19, and auto-antibodies against type I IFN in another 15-20% of cases.
Methods We report here a genome-wide rare variant burden association analysis in 3,269 unvaccinated patients with life-threatening COVID-19 (1,301 previously reported and 1,968 new patients), and 1,373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. A quarter of the patients tested had antibodies against type I IFN (234 of 928) and were excluded from the analysis.
Results No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI:1.5-528.7, P=1.1×10−4), in analyses restricted to biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR=3.70 [95%CI:1.3-8.2], P=2.1×10−4). Adding the recently reported TYK2 COVID-19 locus strengthened this enrichment, particularly under a recessive model (OR=19.65 [95%CI:2.1-2635.4]; P=3.4×10−3). When these 14 loci and TLR7 were considered, all individuals hemizygous (n=20) or homozygous (n=5) for pLOF or bLOF variants were patients (OR=39.19 [95%CI:5.2-5037.0], P=4.7×10−7), who also showed an enrichment in heterozygous variants (OR=2.36 [95%CI:1.0-5.9], P=0.02). Finally, the patients with pLOF or bLOF variants at these 15 loci were significantly younger (mean age [SD]=43.3 [20.3] years) than the other patients (56.0 [17.3] years; P=1.68×10−5).
Conclusions Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old.
Competing Interest Statement
The authors declare no competing financial interests. RN and AKK are employees of Invitae and hold equities in the company. RPL is a member of the board of directors of Roche and its subsidiary Genentech. I Meyts holds a chair in Primary Immunodeficiencies and receives research grant from CSL Behring, paid to KUL. JLC reported a patent to PCT/US2021/042741 pending. FT is head of the Centre de Pharmacoepidemiologie (Cephepi) of the Assistance Publique - Hopitaux de Paris and of the Clinical Research Unit of Pitie-Salpetriere hospital, both these structures have received unrestricted research funding and grants for the research projects handled and fees for consultant activities from a large number of pharmaceutical companies, that have contributed indiscriminately to the salaries of its employees. FT is not employed by these structures and did not receive any personal remuneration from these companies.
Funding Statement
The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimers Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the Investments for the Future program (ANR 10 IAHU 01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR 10 LABX 62 IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR 21 COVR 039), the ANRS COV05, ANR GENVIR (ANR 20 CE93 003) ANR AABIFNCOV (ANR 20 CO11 0001) projects, the ANR RHU program (ANR 21 RHUS 08), the European Unions Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI genomics), the HORIZONHLTH 2021 DISEASE 04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir Fonds de solidarite pour lenfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, The French Ministry of Higher Education, Research, and Innovation (MESRI COVID 19), Institut National de la Sante et de la Recherche Medicale (INSERM), REACTing INSERM and the University of Paris Cite. The study was supported by the ORCHESTRA project, which has received funding from the European Unions Horizon 2020 research and innovation program under grant agreement No 10101616. P Bastard was supported by the MD PhD program of the Imagine Institute (with the support of the Fondation Bettencourt Schueller). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20 0424). The Cov Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health, Fondation AP HP et Programme Hospitalier de Recherche Clinique (PHRC COVID 19 20 0048). H.C.S is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. G.N. and A.N. are supported by Regione Lazio (Research Group Projects 2020) No. A0375 2020 36663, GecoBiomark. I Meyts is a Senior Clinical Investigator at the Research Foundation - Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation program (grant agreement no.948959). This work is supported by the Swiss National Science Foundation (grant #310030L 197721 to JF). This work is supported by ERN RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20 01333, and COV20 01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC 2017 6471 1; AEI/FEDER, UE), co financed by the European Regional Development Funds, A way of making Europe from the European Union, and Cabildo Insular de Tenerife (CGIEU0000219140 and Apuestas cient ificas del ITER para colaborar en la lucha contra la COVID 19). This work was funded, at least in part, by grant AJF202059 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the enrolled participants provided written informed consent for participation and were recruited through protocols conforming to local ethics requirements. Details of ethics approvals are given below: - The French cohorts (French COVID, COVContact and COVIDeF) were approved by the Comite de Protection des Personnes Ile De France VI (2020-A00256-33; 2020-A00280-39; 2020-A00754-35) and Ethics Committee of Erasme Hospital (P2020/203). - The Italian cohorts were approved by the University of Milano-Bicocca School of Medicine, San Gerardo Hospital, Monza-Ethics Committee of the National Institute of Infectious Diseases Lazzaro Spallanzani (84/2020), the Comitato Etico Provinciale (NP 4000-Studio CORONAlab), the local ethics committee at University Hospital of Rome Tor Vergata, the Ethics Committee of San Raffaele Hospital - The Spain cohorts were approved by the Committee for Ethical Research of the Infanta Leonor University Hospital, the Committee for Ethical Research of the 12 de Octubre University Hospital, local ethics committee at the Bellvitge University Hospital, local ethics committee at the University Hospital of Gran Canaria Dr. Negrin, local ethics committee at Vall dHebron University Hospital. - The Swedish COVID cohort was approved by the Swedish Ethical Review Agency
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data supporting the findings of this study are available within the manuscript and supplemental files.
